Speaker Profile
Chief Executive Officer, Myeloid Tx
Biography
Dr. Getts is the CEO and co-founder of Myeloid Therapeutics. Prior to Myeloid, he was the VP of Research at TCR2 (NASDAQ, TCRR) and a member of the leadership team that successfully guided the company through a series B ($120M) financing and an IPO ($80M). Dr. Gettss primary duties were to lead the companys target discovery, preclinical, and translational research programs. These efforts resulted in numerous patent applications, a robust pipeline, and a successfully filed IND. Before TCR2, Dr. Getts was the primary inventor, founder, and CSO of Cour Pharmaceuticals Development Company a nanotechnology platform company focused on autoimmunity and inflammation. As a member of the companys leadership team, he assisted in negotiating several pharmaceutical company collaborations and licenses, including Takeda, which ultimately licensed TIMP-GLIA for $420M. Dr. Getts has received numerous honors and awards, over 10 issued patents, and many more pending patent applications. He is widely published, including over 45 peer-reviewed publications with seminal publications in Nature Biotechnology, Science Translational Medicine, and Nature Communications. Dr. Getts completed his postdoctoral training at Northwestern University in Stephen D. Millers laboratory. He holds a PhD in Medicine from the University of Sydney and an MBA from Western Michigan University.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Cindy Perettie, EVP Kite Pharma
PMWC Award Ceremony
• Michel Sadelain, Columbia
• Arie S. Belldegrun, Allogene Therapeutics
Keynote: Engineering the Future: Innovations in CAR-T Therapy Design
• Michel Sadelain, Columbia
CAR-T Cell Therapies: Strategies in Mitigating Challenges in Solid Tumor Delivery
• Chair: David Barrett, Kite
• Carl June, University of Pennsylvania
• Michel Sadelain, Columbia
Tumor-Infiltrating Lymphocytes (TILs): Advances and Challenges in Solid Tumors
• Chair: Allison Betof Warner, Stanford
• George Coukos, Ludwig Institute for Cancer Research
• Max Julve, Royal Marsden
• Stephanie Goff, NIH/NCI
Allogeneic & In Vivo Cell Therapies: Manufacturing & Clinical Progress
• Chair: Arie S. Belldegrun, Allogene Therapeutics
• David Chang, Allogene Therapeutics
• Adrian Bot, Capstan Therapeutics
• Aliya Omer, AstraZeneca
• Priti Hegde, Kite Pharma
Designing Automated Platforms for Scalable Cell Therapy Manufacturing
Fabian Gerlinghaus (Cellares)
TCR-Based Cell Therapies: New Targets and Clinical Advances
• Chair: Diwakar Davar, UPMC
• Lauren Harshman, Clasp Therapeutics
• Cassian Yee, MD Anderson
Gene Editing & Synthetic Biology for Therapy
• Chair: Matthew Porteus, Stanford
• Rachel Haurwitz, Caribou Biosciences
• Kole T. Roybal, Parker Institute
• Ken Drazan, ArsenalBio
Synthetic Circuits for Smarter Cell Therapies: Enhancing NK Precision and Persistence
Gudrun Stengel, Alida BioSciences
